Compare Incyte Corporation (INCY) vs MGM Resorts International (MGM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs MGM Resorts International — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while MGM Resorts International trades at $29.27 (market cap $7.55B). The key difference: Incyte Corporation is far larger — about 3× MGM Resorts International's market cap, and MGM Resorts International pays a 0.03% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and MGM Resorts International for 91 Days on average.
| INCY | MGM | |
|---|---|---|
Market Cap | $22.85B | $7.55B |
Volume | 1,927,029 | 5,342,346 |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $50.69 |
52-Week Low | $83.80 | $30.00 |
Typical Hold Time | 33 Days | 91 Days |
Enterprise Value | $18.35B | $34.85B |
Dividend Yield | — | 0.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
MGM Resorts International (MGM) trades at $30.01, showing minimal daily movement (+0.03%) amid recent volatility following the collapse of Barry Diller's $48.30 per share acquisition proposal. The stock faces bearish technical signals with oversold RSI readings, while fundamentals show mixed results with Q2 2026 earnings beating expectations but net margins declining to 2.4% in 2025. Recent news highlights potential MGM interest in acquiring People Inc., creating uncertainty around strategic direction.
MGM presents a value opportunity with P/S ratio of 0.45 below industry averages, supported by strong analyst consensus ($48.75 price target, 51% buy ratings). However, risks include declining profit margins, failed acquisition attempts, and ongoing debt burden. The stock's current discount to analyst targets suggests potential upside if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →
